The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s carrying and forwarding (C&F) facility at Wadki in Pune, effective August 27, 2026, following inspections that found multiple alleged regulatory violations involving Reactin Plus Tablets. The prescription medicine, classified as a Schedule H drug, was found carrying the unauthorised claim “analgesic and antipyretic” on its packaging, along with promotional material that the regulator said was not permitted under the Drugs and Cosmetics Act, 1940 and Rules, 1945.
The FDA seized Reactin Plus stock worth ₹11.19 lakh and ordered its recall, but alleged that Cipla did not fully comply with the directions. Subsequent inspections also flagged discrepancies in physical and computerised stock, purchase and sales records, inadequate storage arrangements and medicines kept directly on the floor. Cipla has contested the order and said the matter is under judicial consideration, while maintaining that the FDA action does not raise concerns about the safety, quality or efficacy of its products.
Why Did The FDA Cancel Cipla’s Licence?
The action followed an inspection of Cipla’s main warehouse at Wadki in June. FDA officials found that Reactin Plus packaging described the prescription medicine as an “analgesic and antipyretic”, which authorities said amounted to unauthorised labelling and promotion. FDA Joint Commissioner (Drug) Ganesh Rokade told The Indian Express that “such labelling is not permitted”, adding that such claims on prescription medicines could encourage self-medication and pose a public health risk. The regulator subsequently seized stock valued at ₹11.19 lakh and directed the company to withdraw the affected tablets from the market.
The FDA said a follow-up inspection found further shortcomings in Cipla’s drug sale and distribution system. These included differences between physical and computerised stock, discrepancies in purchase and sales records, inadequate pallets and racks, medicines stored directly on the floor and deficiencies in procedures for dealing with expired medicines. The company was issued a show-cause notice before the regulator examined its response and proceeded with the licence cancellation. FDA Commissioner Tukaram Mundhe said, “Any violation of rules by any entity involved in the manufacture and distribution of medicines will invite strict action as per law.”
What Has Cipla Said?
Cipla has challenged the FDA’s decision, with the company saying the matter is currently under judicial consideration and that it would therefore not be appropriate to comment further on the proceedings. However, it has specifically sought to distinguish the regulatory action from any allegation of a product safety problem. A Cipla Pharma & Life Sciences spokesperson said the FDA order “does not allege any concerns relating to the safety, quality or efficacy of our products” and “does not involve or indicate any patient safety issue”. The licence cancellation, meanwhile, remains effective from August 27 as the legal challenge proceeds.
The case highlights the importance of compliance at every stage of the pharmaceutical supply chain, not only during manufacturing. While the FDA’s findings concern packaging, distribution, storage, records and recall procedures rather than an established defect in Reactin Plus itself, regulators have stressed that prescription medicines require particularly careful handling. For patients, the distinction is important: the allegations reported by the FDA should not automatically be interpreted as proof that the medicine is unsafe or ineffective.
The Logical Indian’s Perspective
Medicines occupy a uniquely sensitive space because people depend on them at moments when they are often vulnerable. Regulatory authorities must therefore be able to enforce rules firmly and transparently, while pharmaceutical companies deserve a fair opportunity to respond through due process. In this case, the FDA’s concerns about prescription-drug labelling, storage and recall compliance merit serious attention, while Cipla’s assertion that there is no identified issue with the safety, quality or efficacy of its products must also be heard as the matter goes through judicial scrutiny.
The larger lesson is that public health is best protected when regulators and pharmaceutical companies prioritise transparency, accountability and patient welfare over defensiveness. Do you think India needs stronger monitoring of how prescription medicines are labelled, stored and recalled?
